PEPGEN INC. Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale
PEPGEN INC. (PEPG) reported Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale of $77.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities · last filed 2026-08-06
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-06-30 was $50.00M, a 233.33% increase year-over-year.
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2026-03-31 was $27.00M, a 12.50% increase year-over-year.
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-12-31 was $21.00M, a 56.25% decline year-over-year.
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for the quarter ending 2025-09-30 was $19.00M, a 36.67% decline year-over-year.
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2025 was $79.00M, a 26.85% decline from fiscal 2024.
- PEPGEN INC. proceeds from maturities, prepayments and calls of debt securities, available-for-sale for fiscal 2024 was $108.00M.
| Period end | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 3 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 6 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 9 month | Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $50.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $77.00M 10-Q · filed 2026-08-06 | $98.00M derived: sum of 3 quarters · filed 2026-08-06 | $117.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $27.00M 10-Q · filed 2026-05-12 | $48.00M derived: sum of 2 quarters · filed 2026-05-12 | $67.00M derived: sum of 3 quarters · filed 2026-05-12 | $82.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $40.00M derived: sum of 2 quarters · filed 2026-03-04 | $55.00M derived: sum of 3 quarters · filed 2026-08-06 | $79.00M 10-K · filed 2026-03-04 |
| 2025-09-30 | $19.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $34.00M derived: sum of 2 quarters · filed 2026-08-06 | $58.00M 10-Q · filed 2025-11-12 | $106.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $39.00M 10-Q · filed 2026-08-06 | $87.00M derived: sum of 3 quarters · filed 2026-08-06 | $117.00M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $24.00M 10-Q · filed 2026-05-12 | $72.00M derived: sum of 2 quarters · filed 2026-05-12 | $102.00M derived: sum of 3 quarters · filed 2026-05-12 | $114.00M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $48.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-04 | $78.00M derived: sum of 2 quarters · filed 2026-03-04 | $90.00M derived: sum of 3 quarters · filed 2026-03-04 | $108.00M 10-K · filed 2026-03-04 |
| 2024-09-30 | $30.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-12 | $42.00M derived: sum of 2 quarters · filed 2025-11-12 | $60.00M 10-Q · filed 2025-11-12 | |
| 2024-06-30 | $12.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $30.00M 10-Q · filed 2025-08-07 | ||
| 2024-03-31 | $18.00M 10-Q · filed 2025-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |